PMID- 22978775
OWN - NLM
STAT- MEDLINE
DCOM- 20130403
LR  - 20221207
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 28
IP  - 10
DP  - 2012 Oct
TI  - Maintenance therapy of gefitinib for non-small-cell lung cancer after first-line 
      chemotherapy regardless of epidermal growth factor receptor mutation: a review in 
      Chinese patients.
PG  - 1699-708
LID - 10.1185/03007995.2012.728525 [doi]
AB  - PURPOSE: Gefitinib is a well known therapy for non-small-cell lung cancer 
      (NSCLC). The purpose of this study was to review clinical reports of gefitinib as 
      maintenance therapy after first-line chemotherapy regardless of epidermal growth 
      factor receptor (EGFR) mutation, and assess its efficacy and safety in Chinese 
      patients. MATERIALS AND METHODS: Systematic computerized searches of the 
      following databases were conducted from the start of each database up to July 
      2012; these include Medline, EMBASE, CNKI and www.clinicaltrials.gov. Terms 
      searched include 'non-small-cell lung cancer', 'NSCLC', 'lung cancer', 'lung 
      tumor', 'gefitinib', 'Iressa', 'EGFR' and 'epidermal growth factor receptor 
      tyrosine kinase inhibitors'. A total of 22 studies were reviewed. RESULTS: In 
      general, the overall response rate (ORR), disease control rate (DCR) and one year 
      survival (OYS) of gefitinib maintenance therapy were 30.89%, 67.5% and 50.6% 
      respectively, in addition, the median overall survival (OS) and median 
      progression free survival (PFS) were 13.09 and 7.88 months respectively. 
      Moreover, ORR, DCR, median survival time (MST) and PFS of female, nonsmoking, 
      lung adenocarcinoma (LAC) patients and patients with rash had higher performance 
      than male, smoking, non-LAC patients and patients without rash (p < 0.05). The 
      adverse events (AEs) were mainly skin rashes and diarrhea, most of which were 
      grades 1 or 2 and were well tolerated. CONCLUSION: Gefitinib produced encouraging 
      efficacy, safety and survival when delivered as maintenance therapy for NSCLC in 
      Chinese patients after first-line chemotherapy regardless of EGFR mutation, 
      especially for the patients who were female, non-smokers, LAC and with rash. Key 
      limitations of this review include limited subgroup data, small sample sizes, and 
      the lack of EGFR/KRAS data.
FAU - Biaoxue, Rong
AU  - Biaoxue R
AD  - Department of Respiratory Medicine, Second Affiliated Hospital, Xi'an Jiaotong 
      University, Xi'an, China.
FAU - Shuanying, Yang
AU  - Shuanying Y
FAU - Wei, Li
AU  - Wei L
FAU - Wei, Zhang
AU  - Wei Z
FAU - Zongjuan, Ming
AU  - Zongjuan M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20121002
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Quinazolines)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - S65743JHBS (Gefitinib)
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - *Asian People
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/ethnology/genetics/mortality
MH  - China
MH  - *ErbB Receptors
MH  - Female
MH  - Gefitinib
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/ethnology/genetics/mortality
MH  - MEDLINE
MH  - Male
MH  - *Mutation
MH  - Quinazolines/*therapeutic use
EDAT- 2012/09/18 06:00
MHDA- 2013/04/04 06:00
CRDT- 2012/09/18 06:00
PHST- 2012/09/18 06:00 [entrez]
PHST- 2012/09/18 06:00 [pubmed]
PHST- 2013/04/04 06:00 [medline]
AID - 10.1185/03007995.2012.728525 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2012 Oct;28(10):1699-708. doi: 10.1185/03007995.2012.728525. 
      Epub 2012 Oct 2.